Premium
Analysis of hematogones in bone marrow from acute myeloid leukaemia cases posttherapy
Author(s) -
Zheng Jine,
Du Wen,
Yao Junxia,
You Yong,
Li Weiming,
He Yanli,
Li Xiaoqing,
Liu Wei,
Wu Yaohui,
Hu Yanjie,
Jin Runming,
Zou Ping,
Huang Shiang,
Hu Yu,
Zhang Min
Publication year - 2013
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.12151
Subject(s) - medicine , immunophenotyping , bone marrow , myeloid leukaemia , myeloid , gastroenterology , immunology , flow cytometry
Background Increased bone marrow ( BM ) hematogones ( HG s) are often observed in patients with marrow regenerating status. Many studies have focused on the role of HG s in acute lymphoblastic leukaemia ( ALL ), but very little has been done to understand their effects on acute myeloid leukaemia ( AML ). Materials and methods Through immunophenotyping, HG s were quantified in 471 BM samples from 292 postchemotherapy AML cases. These samples were analysed to determine whether there is any relationship between HG s percentages and French–American–British ( FAB ) subtypes or risk stratification of AML . Results HG s were identified in 57.75% of 471 patient samples (271) with a mean percentage of 3.87 ± 0.25%. No significant differences were found amongst different FAB subtypes of AML ( P > 0.05). However, significant differences ( P < 0.05) in HG numbers were noted between AML patients experiencing haematological complete remission ( HCR ) and those who have relapsed. HG s were identified in 59.9% of samples under HCR with a mean per cent of 3.98 ± 0.31%, and 36.7% of individuals who have relapsed have detectable HG s with a mean per cent of 1.75 ± 0.47. In addition, HG s in patients groups with low risk or intermediate risk were elevated when compared with high‐risk groups ( P < 0.05), whilst no significant difference was found between low‐risk patients and intermediate‐risk patients ( P > 0.05). Patients with >0.1% of HG s had a significantly better median leukaemia‐free survival ( LFS ) and overall survival ( OS ) than those with <0.1% of HG s ( P < 0.01). Conclusions Therefore, our data indicate that HG s in bone marrow may be used as a favourable prognostic factor that predict for a better outcome of AML patients.